Mode
Text Size
Log in / Sign up
N/A N=19 Other

Smartphone and 3D Printing Based Home Rehabilitation System for Chronic Stroke

Stroke

Enrolled (actual)
19
Serious AEs
0.0%
Results posted
Jan 2024
Primary outcome: Primary: Repetitions Completed for Each Activity in the mRehab Home Program — 282.06; NA; 289.44; NA repetitions

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
mRehab (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
State University of New York at Buffalo
Primary completion
Jul 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Repetitions Completed for Each Activity in the mRehab Home Program
282.06; NA; 289.44; NA; 283.69; NA
PRIMARY
Time to Complete Activity in the mRehab Home Program
4.03; 4.17; 4.01; 4.71; 5.22; 9.28 <0.001 sig
PRIMARY
Average Smoothness Per Activity in the mRehab Home Program
410.66; 768.17; 375.39; 732.16; 492.70; 1869.6 =.228
SECONDARY
Wolf Motor Function Test
15.25; 96.27 =.017 sig
SECONDARY
Nine Hole Peg Test
136.36; 300 =.019 sig
SECONDARY
Difficulty Rating Scale
1.07
SECONDARY
Systems Usability Scale (SUS)
31.25
SECONDARY
mRehab Acceptance Questionnaire
91.56; 106

Summary

Interventions promoting optimum motor performance across the lifespan are a priority after a neurological insult such as stroke. The proposed research incorporates smart devices and 3D printing to create a patient-centered rehabilitation device, mRehab. This innovative blend of technology and principles of neuroplasticity can advance standards of practice in healthcare. In this feasibility study, it is hypothesized that individuals with chronic stroke can successfully use the portable rehabilitation unit, mRehab, at home with minimal oversight from the research team. Use of mRehab in a home based setting and functional changes in upper limb movement will be assessed.

Eligibility Criteria

Individuals in the intervention all had a history of stroke.

Inclusion Criteria for feasibility study:

  • at least 18 years of age and living in the community
  • had a history of one stroke six or more months previous
  • had a minimum score of 124 on the Mattis Dementia Rating Scale (MDRS).

Exclusion Criteria for feasibility study:

  • acute or chronic pain that would interfere with participation
  • severely limited range of motion or contractures of shoulder, elbow, wrist or hand,
  • absent or severely impaired proprioception of the upper limb
  • musculoskeletal or circulatory conditions affecting the upper limb such as vascular disease, tendonitis, cellulitis, Raynaud's syndrome, or severe osteoarthritis or rheumatoid arthritis
  • spasticity graded as 3 or greater for upper extremity movement on the Modified Ashworth Scale (MAS)
  • botulinum toxin injections for spasticity management within three months of starting the study
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04363944). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search